Sponsors:
This activity is jointly sponsored by Postgraduate Institute for Medicine and IMPACt, Inc.
Contact Postgraduate Institute for Medicine
Commercial Support:
This activity is supported by educational grants from
Genentech BioOncology and sanofi-aventis, US.
Description:
"Virtual Colorectal Tumor Board: Targeted Therapies in Advanced Cases" is a case-based discussion that focuses on integrating targeted therapies into the treatment of late stage colorectal cancer. The panel of experts will discuss the most appropriate management options for the cases and emphasize a multidisciplinary team approach to treatment.
Learning Objectives:
1. Outline how to implement evidence-based strategies to safely and effectively optimize cytotoxic and targeted agents for patients diagnosed with advanced colorectal cancer (CRC) based on the cases presented
2. Describe targeted therapy options in front-line metastatic CRC
3. Identify predictive markers including a patient’s KRAS status that may guide better selection of treatment approaches for individual patients
4. Recall the definition of resectable hepatic metastasis and the importance of integrating systemic therapy with surgery
5. Define a concept of continuum of care in Stage IV CRC including 1st line treatment and treatment for relapsed disease
Target Audience:
This activity has been designed to meet the educational needs of medical oncologists and surgeons involved in the care of patients with colorectal cancer.
Accreditation Statement:
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Postgraduate Institute for Medicine (PIM) and IMPACt, Inc. PIM is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation:
Postgraduate Institute for Medicine designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Agenda:
This activity will explore one borderline or potentially resectable patient with metastatic colorectal cancer.
1st Line Therapy discussion
- The role of EGF and VEGF receptor antagonists with systemic chemotherapy
- Should all tumors be examined for the KRAS mutation?
- Patient progresses on first line
2nd Line Therapy
- BRITE trial
- Spirit
- IBET Trial
Ultimately patient goes to surgery
- Should adjuvant/maintenance therapy be offered?
- What about bevacizumab (patient previously progressed on bevacizumab?)
- 14 month DFI
Relapse/recurrence
- Lung met?
- Liver toxicity issues
- BOND-2 Trial
Third-Line Therapy choices
Faculty:
Anton Bilchik, MD, PhD, FACS (Course Director)
Medical Director of California Oncology Research Institute
Clinical Professor
UCLA School of Medicine
.jpg)
J. Randolph Hecht, MD
Professor of Clinical Medicine
Director, UCLA GI Oncology Program
Zev Wainberg, MD
Assistant Professor of Medicine
UCLA School of Medicine
Disclosure of Conflicts of Interest:
Postgraduate Institute for Medicine (PIM) assesses conflict of interest with its instructors, planners, managers and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by PIM for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Anton Bilchik, MD, PhD, FACS
Consulting fees: Adolor, GlaxoSmithKline, sanofi-aventis, US
J. Randolph Hecht, MD
No significant financial relationship with any commercial entity related to this activity
Zev Wainberg, MD
Consulting fees: Bristol-Myers Squibb, Genentech, Pfizer
The following planners and managers, Linda Graham, RN, BSN, BA, Jan Hixon, RN, BSN, MA, Trace Hutchison, PharmD, Scott McMahon, and Jan Schultz, RN, MSN, CCMEP hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interests related to the content of this CME activity.